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ABSTRACT
Breast cancer is responsible for 25% of cancer cases and 15% of cancer death 
among women. Treatment is usually prolonged and hampered by the development 
of chemoresistance. The molecular mechanisms maintaining the chemoresistant 
phenotype remains, however, largely obscure. As kinase signaling in general is 
highly drugable, identification of kinases essential for maintaining chemoresistance 
could prove therapeutically useful. Hence we compared cellular kinase activity in 
chemotherapy resistant MCF7Res cells to chemotherapy-sensitive MCF cells using 
a peptide array approach that provides an atlas of cellular kinase activities and 
consequently, predominant pathways can be identified. We observed that peptides 
phosphorylated by elements of JAK-STAT signaling pathway and PKC signaling 
pathways are subject to extensive kinase activity in MCF7Res cells as compared to 
chemotherapy-sensitive MCF cells; and Western blotting confirmed relatively strong 
activation of these signaling pathways in chemoresistant cells. Importantly, treatment 
of cells with Tofacitinib, a FDA-approved JAK inhibitor, converted chemoresistant cells 
to chemosensitive cells, inducing apoptosis when used in conjunction with doxorubicin. 
Thus our results reveal that chemoresistance in breast cancer is associated with 
activation of JAK/STAT signaling and suggest that JAK2 may be useful for combating 
chemoresistance in breast cancer.
INTRODUCTION
It has been estimated that annually 1.7 million 
new cases of breast cancer are diagnosed around the 
world [1]. In general, breast cancer is one of the most 
prominent causes of cancer-related deaths among women, 
amounting to 25% of cancer cases and 15% of cancer 
deaths in females [2]. Despite advances in therapy, clinical 
outcome of breast cancer thus remains unsatisfactory. 
It is hoped that the unrelenting advance in knowledge 
of the molecular basis of breast cancer will ultimately 
reveal novel molecular targets for therapy [3], but 
currently the main challenge in combating breast cancer 
lies in the development of chemotherapeutic resistance 
following the xenobiotic administration that characterizes 
contemporary treatment protocols. In molecular terms this 
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chemoresistant aspect of breast cancer is denominated as 
the MDR cell phenotype [4]. As MDR is multifactorial 
in nature, the MDR phenotype has been associated with 
multiple cellular changes, including changes in cell cycle 
patterns, increased efficiency of DNA repair, reduction 
of apoptotic propensity and modification of drug 
metabolism [5]. Although the mechanisms mediating the 
MDR phenotype remain only partly resolved, the notion 
that activation of specific signaling pathways, e.g. PI3K/
AKT or Ras/ERK pathway maintain this phenotype has 
been gaining ground [6, 7, 8]. In breast cancer, however, 
candidate pathways mediating the MDR phenotype have 
not been conclusively identified, hampering rational 
treatment of disease.
Identifying pathways mediating MDR in cancer 
cells has been traditionally hampered the necessity of 
pursuing one potential biochemical element involved in 
this process at a time. Classically, the study of different 
signaling pathways typically occurs by analyzing the 
phosphorylated/dephosphorylated amino-acid residues of 
proteins, which is basically conducted by western blotting 
approaches. However, this technique is labor intensive 
and does not allow the analysis of multiple proteins 
simultaneously and therefore it is limiting for clinical 
studies and also makes it time consuming to identify 
potential new molecular targets [9, 10]. Novel therapeutic 
approaches, however, provide potential for progress in 
this regard. Especially kinome profiling using peptide 
arrays allows the simultaneous analysis of over 1000 
substrates in a single experiment thus creating more-or-
less comprehensive descriptions of cellular global kinase 
activity [11]. This technology is now revolutionizing 
signal transduction research and has been successfully 
employed for kinase activity profiling, biomarkers 
Figure 1: Cellular viability assessed by the mitochondrial function, differential expression of Ras, p44/42-mapk, 
GSK3ß and MMP-9. (a) Schematic depiction of the experimental design employed for this study; (b) a dose-response curve to drug 
treatment - Cytotoxicity of doxorubicin at various concentrations for MCF7 or MCF7Res cells was determined following 24h drug 
treatment as described in Methods. The means of at least three independent experiments are plotted. Cell viability was assessed by the 
ability of cells to reduce MTT salt (vital stain) as described in Materials & Methods. Our results show a difference in the viability of the 
tested lineages. Cells were cultured under routine classic conditions. In the semi-confluence, the cells were lysed using standard lysing 
buffer (described in M&M) and resolved on SDS-PAGE gel following transfer to PVDF membranes and staining using specific primary 
antibodies; (c) representative blots following probing for Ras, p44/42-mapk (Erk 1/2), GSK3ß and MMP-9 are shown, as well as their 
arbitrary values obtained by densitometric analysis; (d-g, respectively) normalized to the average values of the respective bands of ß-Actin 
for the appropriate conditions. # means statistical significance (test t-student). The ß-Actin was used as loading sample (approximately 75μg 
of protein per lane). The differences were significant when *p<0.05.
Oncotarget114758www.impactjournals.com/oncotarget
identification, cell surface marker/glycosylation profile, 
clinical diagnosis and environmental and food safety 
analysis [12, 13]. This powerful approach has however 
not been exploited to obtain insight into the biochemical 
pathways maintaining the MDR phenotype in cancer. 
The clinical problem posed by chemoresistance in breast 
cancer, however, urges of application of this technology 
for especially this disease.
The above-mentioned considerations prompted us 
to contrast the kinome of chemotherapy sensitive and 
chemotherapy-resistant MCF cancer cells. Importantly, we 
validated the kinome profiling results by western blotting 
technology applied to identify the involvement of PKCs 
isoforms. Conversely, we observe that chemoresistance 
in breast cancer is associated with activation of JAK2-
STAT pathways and that inhibition by using a FDA-
approved inhibitor (Tofacitinib) of the latter pathway 
reverts chemoresistant cancer cells to a chemosensitive 
phenotype, provoking apoptosis when used in combination 
with doxorubicin. Thus, our results showed that JAK2 
inhibition is a rational strategy to combat chemoresistance 
in breast cancer.
RESULTS
Firstly, we confirmed that our experimental set up 
allows investigation of chemoresistance in breast cancer. 
To this end we compared doxorubicin dose-responses 
curves of MCF7 cells to MCF7Res cells with respect to 
the ability of viable cells to reduce MTT salt (vital stain, 
experimental flow in Figure 1a). The results show that 
whereas the maternal MCF7 cell line is highly sensitive 
to doxorubicin (displaying an apparent of 10 μM – 62.5 
μM), the MCF7Res culture exhibits an IC50 between 500 
μM to 1000 μM (Figure 1b). We thus concluded that our 
setup was suitable for investigating the molecular basis of 
chemoresistance.
Encouragingly, a preliminary comparison of the 
maternal MCF7 cell line with MCF7Res cells for signaling 
elements generally associated with chemoresistance 
showed that the chemoresistant phenotype was associated 
with increased expression of p21Ras and MMP9 and 
reduced expression of GSK3ß, whereas increased 
phosphorylation was noted of p44/42-MAPK (Figure 1c-
1g). Thus biochemical differences between the resistant 
phenotype and chemosensitive manifestation of MCF7 
cells exist and experiments were initiated to identify the 
underlying signal transduction events.
A kinome fingerprint of chemoresistant breast 
cancer
We contrasted the kinome of the maternal 
chemosensitive MCF7 cell line to that of the 
chemoresistant MCF7Res cultures. To this end cultures 
were lysed and resulting lysates were used for in vitro 
phosphorylation of peptide arrays exhibiting more as 
thousand different kinase substrates. Our results show that 
Figure 2: (a) Median phosphorylation intensity for all 1024 PepChip kinases and substrates. Colored spots signify individual peptide 
phosphorylations that exhibit statistically significant differences between the experimental conditions (p<0.05). Red means down 
regulation of phosphorylation (FC<0.75) whereas green indicates an upregulation of phosphorylation (FC>1.5) in the experimental sample 
as compared to the control sample. Grey lines represent FoldChange = 0.5; 1; 2, top to bottom. Spots are identified by the phosphorylated 
substrate (denoted by “p”), followed by the kinase putatively responsible for the phosphorylation event. FC indicates the individual fold 
change for each colored spot. (b) Protein network depicting interactions among protein kinase C variants and proteins found with altered 
phosphorylation profiles. Blue lines indicate binding, green lines indicate activation and red lines indicate inhibition, whereas purple lines 
indicate catalysis, pink lines indicate posttranslational modification, yellow lines indicate transcriptional regulation and black lines indicate 
a generic reaction. Arrows indicate a positive action, bars indicate a negative action and ball-ends indicate a directional interaction of 
unknown nature. Proteins are represented by gene names. The network was generated by STRING 10.0 [19].
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Figure 3: Expression and differential phosphorylations of PKCα, pPKCαβII, total-PKC, pPKC pan-βII, PKCδ, pPKCδθ 
and PLCγ. The cells were cultured under routine classic conditions. In the semi-confluence, the cells were lysed using standard lysing 
buffer (described in M&M), and proteins were resolved on SDS-PAGE gel and after PVDF membrane transfer, interrogated for expression 
using specific primary antibodies. ß-Actin was used as loading control (approximately 75 μg of protein per lane). (a) Representative blotting 
for total-PKC, PKCα and pPKCαβII proteins (a), and respective arbitrary values obtained by densitometric analysis normalized by the 
loading controls (b-e). (f) Representative blotting for pPKCαβII and respective arbitrary values obtained by densitometric analysis and 
normalized by the average values of the respective total-PKC and ß-Actin bands (g, h). (i) Representative blottings for pPKCδθ and PKCδ 
proteins. Graphs (j) and (k) represent arbitrary values obtained by densitometric analysis of pPKCδθ bands normalized by the average 
values of the ß-Actin and total-PKC bands, respectively. When normalized by total-PKC, the proteins PKCδ and pPKCδθ were differentially 
expressed between the two lineages studied. (l) Representative blotting of PKCζ protein. Graph (m) represents arbitrary values obtained by 
densitometric analysis of PKCζ bands normalized by the average values of the total-PKC bands. When normalized by total-PKC, the protein 
PKCζ was differentially expressed between the two lineages studied. Differences were considered significant when *p<0.05.
Figure 4: Expression and differential phosphorylation of PKD/PKCμ and PLCγ. (a) Representative blotting of pPKD/ PKCμ 
and PKD/PKCμ proteins. Arbitrary values obtained by densitometric analysis of pPKD/PKCμ and PKD/PKCμ bands normalized (b-d). 
(e) Representative blotting of PLCγ protein. Graph (f) represents arbitrary values obtained by densitometric analysis of the PLCγ bands 
normalized by the average values of the ß-Actin bands. When normalized by ß-Actin, the protein PLCγ presented significant difference 
between the two lineages studied. Differences were considered significant when *p<0.05.
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the kinome of chemoresistant cells is markedly different 
from chemosensitive cultures (Figure 2a; Supplementary 
Table 1). Interesting substrates differentially 
phosphorylated include GNAT2, NCF1 and SRF that are 
subject to phosphorylation by PKC isoforms and Casein 
Kinase 2 (CK2) respectively. A network analysis confirms 
a central role for PKC variants (Figure 2b). We concluded 
that chemoresistance of breast cancer cells is associated 
with a specific kinome profile in which PKC activation 
has a prominent role.
PKCs isoform are both differentially 
expressed and phosphorylated in breast cancer 
chemoresistant phenotype
Independent confirmation for the notion that 
chemoresistance of breast cancer cultures is associated 
with activation of PKC was obtained from experiments 
in which we directly assessed both PKC expression and 
phosphorylation of different PKC isoforms including 
PKCα, pPKCαβII, pPKC pan-βII, PKD/PKCμ, pPKD/
PKCμ, PKCζ, PKCδ, pPKCδθ as well as total PKC 
Figure 5: Protein network depicting interactions among protein kinase C variants and their potential substrates. 
For generating the network the existing information of protein-protein interaction in the body of contemporary biomedical literature was 
exploited. Blue lines indicate direct binding between partnering molecules, green lines indicate activation and red lines indicate inhibition, 
whereas purple lines indicate catalysis, pink lines indicate posttranslational modification, yellow lines indicate transcriptional regulation 
and black lines indicate a generic reaction. Arrows indicate a positive action, bars indicate a negative action and ball-ends indicate a 
directional interaction of unknown nature. Proteins are represented by gene names. The network was generated by STRING 10.0 [19].
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(Figure 3). The results show differential PKC activation/
inactivation in chemoresistant breast cancer cells, in which 
especially the phosphorylations of pPKCαβII (Thr638/641) 
(Figure 3a, 3b) and pPKD/PKCμ (Ser744/748) (Figure 
4a-4d) is significantly up-regulated, whereas the 
phosphorylation of atypical pPKCδθ (Ser643/676) (Figure 
3i, 3j) is significantly and substantially reduced. In line 
with its canonical mode of action, expression of PLCγ 
(that activates classical PKCs by liberating diacylglycerol 
from biological membranes) was strongly upregulated in 
chemoresistant cells (Figure 4e, 4f). The only exception 
to the activation of classical PKCs came appeared to be 
PKCβII as an anti- PKC pan-βII (Ser660) antibody failed 
to detect differences between the groups (Figure 3f-3h) 
and hence chemoresistance of breast cancer cells involves 
prominent activation of classical PKCs.
Detailed network analysis
Subsequently we decided to further mine our data 
for relevant signaling events, especially in view of the 
relative unsuitability of PKC as a drug target. This can 
be done by challenging the data in the bioinformatical 
protein network generated by STRING 10.0 [19] using 
PKC variants as core proteins. Surprisingly a relevant 
involvement with JAK-STAT signaling in chemoresistant 
cells (Figure 5) emerged, prompting investigation of the 
role of this signaling in breast cancer chemoresistance.
STATs are significantly up-phosphorylated in 
chemoresistant breast cancer cells
In order to address the issue of JAK/STAT signaling 
in maintaining chemoresistance, we interrogated the 
phosphorylation status of various STATs including STAT1 
(Y701) (Figure 6d, 6f), STAT2 (Y690) (Figure 6d, 6g), 
STAT3 (Y705) (Figure 6d, 6h), STAT5 (Y694) (Figure 6d, 
6i) and STAT6 (Y641) (Figure 6d, 6j), as well as JAK1 and 
JAK2. All of the Stats investigated displayed significantly 
increased–phosphorylation in chemoresistant cancer 
cells. Likewise expression of both JAK1 and JAK2 were 
significantly upregulated in the chemoresistant phenotype 
Figure 6: Differential JAK-STAT signaling involvement. Cells were cultured under routine conditions. In the semi-confluence, 
the cells were lysed using standard lysing buffer (described in M&M), the whole protein was resolved on SDS-PAGE gel and after PVDF 
membrane transfer, these were identified by using specific primary antibodies. (a) Representative blottings for Jak1 and pJak2. Graphs 
(b) and (c) represents arbitrary values obtained by densitometric analysis of Jak1 and pJak2 bands normalized by the average values of 
the ß- Actin bands. Statistical analysis showed that effects with respect to Jak1 andJak2 were significant resistance. ß-Actin was used as 
loading control (approximately 75 μg of protein per lane). (d) Representative blotting for pStat1, pStat2, pStat3, pStat5 and pStat6. (e) 
Representative blotting for ß- Actin. Arbitrary values obtained by densitometric analysis and normalized for ß- Actin are shown as well 
(f-j). Differences were considered significant when *p<0.05.
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(Figure 6a-6c), and especially phosphorylation of JAK2 
was very prominent in this cell type, suggesting that the 
latter kinase is involved in maintaining the chemoresistant 
phenotype.
This notion was substantiated by experiments in 
which we tested the effect of two JAK2 inhibitors, [(E)-
3-(6-bromopyridin-2-yl)-2-cyano-N-((S)-1-phenylethyl) 
acrylamide, WP1066] and FDA-approved Tofacitinib in 
the presence and absence of doxorubicin (Figure 7a) on 
the resistant breast cancer cells. WP1066 itself exerted 
no cytotoxicity at 5μM or 10μM. However, when cells 
were pretreated for two hours with 5μM or 10μM of the 
WP1066 and cells were subsequently challenged with 
doxorubicin for 24 hours, chemosensitivity of MCF7Res 
Figure 7: JAK inhibitor (Tofacitinib) sensitizes MCF7-Res cells to doxorubicin. (a) Chemical structures of the WP1006 
and Tofacitinib. (b) a Jak2 inhibitor sensitizes to chemotherapy in breast cancer cells. Cells were plated in 96 well plates and at the 
semi-confluence were treated with the concentrations of 5μM and 10μM inhibitor of Jak2 [(E)-3-(6-bromopyridin-2-yl)-2-cyano-N-((S)-
1-phenylethyl) acrylamide, WP1066] for 2 hours. After this period, all the groups were treated with 10μM of doxorubicin for 24 hours, 
while the viable cells were monitored by MTT reduction capacity. Both concentrations significantly sensitized [5μM (* p <0.05) and 
10μM (**p <0.001)] cells initially resistant to doxorubicin (doxo). (c) Viable cells quantified by trypan blue. The MCF7-Res cells viability 
decrease in Tofacitinib and Doxorubicin treatment, indicated by 5μM and 10μM of Tofacitinib. Data are represented as mean ± S.E.M. (d) 
Flow cytometry to apoptosis assay. MCF7 and MCF7-Res cells were exposed to 5μM and 10μM of Tofacitinib for 2 hours; after treated 
with Doxorubicin 5μM for 24 hours. After treatment, the apoptosis was analyzed by a flow cytometer using annexin-V/7-AAD double-
staining assay. Early apoptosis (annexin-V positive, 7-AAD negative), late apoptosis (double-positive cells), and non-apoptotic cell death 
(annexin-V negative, 7-AAD positive) are shown, as percentage. The difference of sensitivity to Doxorubicin monotherapy and co-therapy 
with Tofacitinib between MCF7 and MCF7-Res is indicated by (*) (5μM) and (**) (10μM) in favor for Tofacitinib co-therapy.
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cell line was clearly evident [5μM (p<0.05) and 10μM 
(p<0.001)] (Figure 7b). Additionally, the same cellular 
response profile was observed in the case of combined 
treatment with Tofacitinib and doxorubicin (Figure 7c). 
Importantly, the drugs combination was more efficient in 
triggering late apoptosis (Figure 7d).
In addition, the Figure 8 shows the protein network 
depicting interactions among JAK-STAT signaling 
pathway proteins (extracted from KEGG [20]) and 
proteins found with altered phosphorylation profiles 
in the phosphoproteomes obtained from breast cancer 
chemoresistant cells. Note the involvement of the JAK-
STAT signaling with proteins related with cell proliferation 
(MAPKs, Raf-1), cytoskeleton rearrangement (RhoA), 
cell survival (PI3K, IRS, AKT1) and control of protein 
synthesis (mTOR). In conjunction, these data reveal a 
clear role for JAK-STAT signaling in maintaining the 
chemoresistant phenotype in breast cancer. The Figure 9 
brings an overview of the relevant findings encountered 
in this study.
DISCUSSION
One of the major obstacles in the treatment of cancer 
patients is to overcome resistance to chemotherapeutic 
agents. Therefore, the elucidation of mechanisms 
responsible to resistance to drugs with different chemical 
structures and targets in order to develop of new protocols 
for treating cancer-based disorders is very urgent called 
for. Here we tried to address this issue by contrasting 
kinome patterns in chemoresistant and chemosensitive 
MCF7 cultures. The results reveal that chemoresistance 
is associated with activation of classical PKCs but also 
that the chemoresistant phenotype is dependent on JAK2 
signaling. As JAK2 is pharmaceutically relatively easy 
to target (e.g. the pan-JAK inhibitor tofacitinib is already 
routinely used for the treatment of inflammatory and 
neoplastic diseases [21]), these results strongly argue 
for clinical studies into the potential of JAK inhibitors 
to combat clinical chemoresistance in breast cancer. In 
addition, the multitude of kinases identified associated 
Figure 8: Protein network depicting interactions among Jak-Stat signaling pathway proteins (extracted from KEGG) 
and proteins found with altered phosphorylation profiles. Blue lines indicate binding, green lines indicate activation and red 
lines indicate inhibition, whereas purple lines indicate catalysis, pink lines indicate posttranslational modification, yellow lines indicate 
transcriptional regulation and black lines indicate a generic reaction. Arrows indicate a positive action, bars indicate a negative action and 
ball-ends indicate a directional interaction of unknown nature. Proteins are represented by gene names. The network was generated by 
STRING 10.0 [19].
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with the chemoresistant phenotype may also serve as a 
biomarker fingerprint for resistance development in the 
treatment of breast cancer.
Regarding the involvement of PKCs, an apparent 
paradox is present in our results: PKCαβII and PKD/
PKCμ are differentially regulated as compared to PKCα 
and PKCδ in relation to the chemoresistant phenotype. The 
results correspond, however, with those of Koivunen et al. 
(2006) [22] who showed that PKCαβII phosphorylation 
positively correlates to a malignant phenotype in breast 
cancer. Likewise, overexpression of PKD/PKCμ correlates 
to chemoresistance in various cell types and is associated 
to increased proliferation and metastasis, possibly 
through activation of the PI3K-Akt and the Raf1-Mek-
erk (p42/p44-MAPK) pathway [23]. We observed that 
activation of p42/p44-MAPK, overexpression of MMP-
9 and downregulation of GSK3β in MCF7Res cells, 
which mirrors earlier observations of Kim et al. (2007) 
[24]. These authors showed that inhibition of GSK3β is 
necessary to maintain high MMP-9 levels through the 
activation of p42/p44-MAPK and a similar mechanism 
appears operative in MCFRes cultures. It is thus tempting 
to speculate that PKD/PKCμ contributes, together down-
regulation of GSK3β and up-regulation of p42/p44-MAPK 
to the MDR-phenotype in breast cancer, concomitantly 
driving MMP-9 overexpression and thus metastasis. 
Such a scheme would fit well with earlier observations 
of higher PKD/PKCμ patterns in the MDR phenotype in 
breast cancer cells [25]. However, further studies remain 
necessary to prove this point.
Our observation of the strong activation of classical 
PKCs in chemoresistant breast cancer may help to bring 
clarity in a very controversial body of literature. At 
present current literature contains very contradictory 
results on the role of PKCα in chemoresistance, different 
groups reporting apparently contradictorily results. 
Importantly, though PKCα phosphorylation is usually 
increased in TAMR (tamoxifen-resistant) breast cancer 
cells when compared to TAMS (tamoxifen-sensitive) 
breast cancer cells [26]. In addition, it has been reported 
that PKCδ is a tumor suppressor protein [27] and also 
involved with metastatic progression [28]. We show PKC 
isoforms are highly differentially regulated with respect 
to chemoresistance in breast cancer cells, which may 
Figure 9: Signal transduction mechanisms involved in the resistance of breast tumor cells. Schematic proposed mechanism 
of JAK-STAT signaling pathway and PKC activation and the relation to the acquisition of resistance to chemotherapeutic agents. The 
scheme shows elements actively investigated in this study and illustrates the potential to construct metabolic maps from kinome data.
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explain disparity in earlier results. In this context our 
results with regard to PLCγ expression may be relevant. 
PLCγ hydrolyzes phosphatidylinositol 4,5-bisphosphate 
to generate the second messengers, inositol 
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). 
In turn, IP3 induces a transient release of intracellular 
free Ca2+ mainly from smooth endoplasmic reticulum, 
while DAG directly activates protein kinase C. Thus, 
traditional or conventional PKCs (cPKC) composed of 
PKCα, PKCβI, PKCβII and PKCγ are calcium-dependent 
and activated by phosphatidylserine (PS) and DAG. Our 
results show that PLCγ is overexpressed in MCF7Res 
cells and correlates to PKCβII phosphorylation. In view 
of the potential role of PLCγ in PKC activation, it has 
been suggested that its inhibition is an appropriate target 
to limit the metastatic potential of malignant cells [29-31]. 
Our results corroborate this notion. Generally speaking, 
however, PLC inhibitors with an acceptable toxicity 
profile are not available and thus clinical validation of 
this hypothesis cannot be done right now. In addition, 
if considering the critical roles of PKC signaling in 
both normal physiology and disease, even selectively 
targeting specific PKC isoforms may be associated with 
unacceptable toxicity and side effects.
In conclusion, we feel that our study provides a 
wealth of information on the biochemical events linked 
to development of the chemoresistant phenotype in breast 
cancer cells and especially implicates PKC and JAK/STAT 
signaling in this phenomenon. In view of the availability 
of approved JAK inhibitors, our results argue for clinical 
trials testing the potential of such inhibitors for combating 
breast cancer chemoresistance.
MATERIALS AND METHODS
Antibodies, chips and JAK inhibitors
The following antibodies were purchased from Cell 
Signaling (Danvers, MA, USA): JAK1 Antibody (#3332, 
130kDa), Phospho-JAK2 (Tyr1007/1008) Antibody 
(#3771, 125kDa), β-Actin Antibody (#4967, 45kDa), 
Phospho-STAT1 (Tyr701) (58D6) Rabbit mAb (#9167, 
84,91kDa), Phospho-STAT2 (Tyr690) Antibody (#4441, 
113kDa), Phospho-STAT3 (Tyr705) Antibody (#9131, 
79,86kDa), Phospho-STAT5 (Tyr694) Antibody (#9351, 
90kDa), Phospho-STAT6 (Tyr641) Antibody (#9361, 
110kDa), Ras Antibody (#3965, 21kDa), p44/42-MAPK 
(Erk1/2) Antibody (#9102, 42,44kDa), GSK-3β (27C10) 
Rabbit mAb (#9315, 46kDa), MMP-9 Antibody (#3852, 
84,92kDa), Phospho-PKCα/β II (Thr638/641) Antibody 
(#9375, 80,82kDa); PKCα Antibody (#2056, 80kDa); 
Phospho-PKC (pan) (βII Ser660) Antibody (#9371, 78 
a 85kDa); Phospho-PKD/PKCμ (Ser744/748) Antibody 
(#2054, 115kDa); PKD/PKCμ Antibody (#2052, 115kDa); 
PKCδ Antibody (#2058, 78kDa); Phospho-PKCδ/θ 
(Ser643/676) Antibody (#9376, 78kDa), PKCζ Antibody 
(#9372, 78kDa); PLCγ1 Antibody (#2822, 155kDa); anti-
mouse, anti-rabbit and anti-goat IgGs antibodies. From 
Abcam (Cambridge, MA, USA): anti-PKC antibody 
(ab59363) was purchased. PepChip1-KinomicsTM slides 
were obtained from Pepscan Presto BV (Lelystad, the 
Netherlands).
WP1066 (#573097; C17H14BrN3O) and Tofacitinib 
(#PZ0017; C16H20N6O · C6H8O7) were purchased from 
Sigma-Aldrich (St. Louis, MO, USA).
Cell line and culture conditions
The MCF7 cell line was purchased from the ATCC 
(ATCC, Manassas, VA, USA), and routinely cultured in 
DMEM medium supplemented with 10% FBS, 4mM 
glutamine, 1mM sodium pyruvate, 100 IU/mL penicillin 
and 100μg/mL streptomycin. Doxorubicin resistant 
variant cells (MCF7Res) derived from MCF7 cells were 
continuously cultured in the medium as described above 
containing additional 500nM doxorubicin (Sigma-Aldrich, 
St Louis, MO, USA), along with the parental MCF7-cells 
under identical culture conditions except that the control 
cells were treated with 0.1% ethanol. The two cell lines 
were grown side by side at all times. Cultures were 
maintained in 5% carbon dioxide at a temperature of 37°C.
Cell viability was determined by MTT reduction
Both MCF7 and MCF7Res were plated into 96-well 
plates, 10,000 cell/well. Forty-eight hours later, the culture 
medium was replaced by fresh medium containing various 
concentrations of doxorubicin for 24h. The percentages 
of viable cells were then determined by the conversion of 
the water soluble MTT (3-(4,5-dimethylthiazol-2yl)-2,5-
diphenyltetrazolium bromide) to an insoluble formazan, 
relative to drug free controls. All cytotoxicity data shown 
are the means of at least three independent experiments. 
Results of the MTT cell proliferation assay were analyzed 
using the GraphPad PRISM 6.0 software (GraphPad 
Software, Inc.). The inhibitory concentration (IC50) 
values, which are the drug concentration at which 50% of 
cells are viable, were calculated from the logarithmic trend 
line of the cytotoxicity graphs.
Peptide microarray-based phosphoproteome
Kinome array analysis was done as described by 
Diks et al. [14] and van Baal et al. [15]. Furthermore, 
the protocol of the kinome array is described in detail 
on the Web site (http://www.pepscan.nl/pdf/Manual%20
PepChip%20Kinase%200203.pdf). In short, cells were 
washed in PBS and lysed in a non-denaturing complete 
lysis buffer. The peptide arrays (Pepscan Presto BV), 
containing up to 1,024 different kinase substrates (in 
triplicate), were incubated with cell lysates for 2h in a 
humidified stove at 37°C plus 33P-γ-ATP. Subsequently, 
the arrays were washed in 2 M NaCl, 1% Triton-X-100, 
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PBS, 0.1% Tween, and H2O, where after arrays were 
exposed to a phospho-imaging screen for 72 h and scanned 
on a phospho-imager (Fuji Storm 860, Stanford, GE). The 
density of the spots was measured and analyzed with array 
software.
Immunoblotings
MCF7Res and MCF7 were routinely cultured and 
protein extracts were obtained using lysis cocktail (50 
mM Tris [tris(hydroxymethy- l)aminomethane]–HCl 
[pH 7.4], 1% Tween-20, 0.25% sodium deoxycholate, 
150 mM NaCl, 1 mM ethylene glycol tetraacetic acid 
(EGTA), 1 mM O-Vanadate, 1 mM NaF, and protease 
inhibitors [1 mg/ml aprotinin, 10 mg/ml leupeptin, 
and 1 mM 4-(2-amino- ethyl)-benzolsulfonyl-fluoride-
hydrochloride]) for 2 h on ice, as used previously by de 
Souza Queiroz et al. (2007) [16] and de Fátima et al. 
(2008) [17]. After clearing by centrifugation, protein 
concentration was determined using the Lowry method 
[18]. An equal volume of 2-sodium dodecyl sulfate (SDS) 
gel loading buffer (100 mM Tris–HCl [pH 6.8], 200 mM 
dithiothreitol [DTT], 4% SDS, 0.1% bromophenol blue, 
and 20% glycerol) was added to samples and boiled for 
5 min. Protein extracts were resolved by SDS–PAGE 
(10% or 12%) and transferred to PVDF membranes 
(Millipore). Membranes were blocked with either 1% 
fat-free dried milk or bovine serum albumin (2.5%) 
in Tris-buffered saline (TBS)–Tween-20 (0.05%) and 
incubated overnight at 48C with appropriate primary 
antibody at 1:1.000 dilutions. After washing in TBS–
Tween-20 (0.05%), membranes were incubated with 
horseradish peroxidase- conjugated anti-rabbit, anti-goat, 
or anti-mouse IgGs antibodies, at 1:2.000 dilutions (in all 
immunoblotting assays), in blocking buffer for 1h. When 
it was necessary to investigate more than one protein on 
the same blot, stripping of the membranes was performed 
as recommended by Abcam (Cambridge, MA, USA), 
while taking special care to avoid contamination with 
traces of ß-mercaptoethanol, as this may damage antibody 
conformation. Detection was performed using enhanced 
chemiluminescence (ECL). For all Western blots ß-actin 
was used as an (additional) internal control.
Phosphoproteome data analysis
Datasets from chips were generated by EisenLab 
ScanAlyze, version 2.50, array software, and then 
submitted to a statistical spot reliability approach 
called PepMatrix [32]. Data on each chip are generated 
in triplicate (i.e. the result of three different peptide 
phosphorylation reactions, as each peptide is present in 
triplicate). Intra-array variation with respect to identical 
phosphorylation of identical peptide as assessed for 
consistency using two indexes: standard deviation/
average ratio (SD/A) and the ratio between average and 
median (A/M). Selected threshold parameters for this 
analysis were SD/A < 20% and 80% < A/M < 120%. 
Every spot that did not pass both these thresholds in any 
of the chips involved in this experimentation was rejected 
in not subjected to further analysis in our pipeline. 
The remaining data was studied according to standard 
statistical analysis and included calculation of fold change 
and t-tests (two-tailed, heteroscedastic) for identifying 
significantly different peptide phosphorylation between 
the experimental conditions (p < 0.05). Corresponding 
proteins represented by the oligopeptides used for 
substate phosphorylation were then analyzed using protein 
interaction data from databases such as HPRD [33] and 
UniProt (The UniProt Consortium) [34] to identify kinases 
and signaling pathways potentially affected in the different 
experimental conditions. Afterwards, altered kinase 
activities were validated by more specific methods, such 
as western blotting, and positive matches were studied in 
further detail as described herein.
Functional approaches to estimate JAK/STAT 
signaling involvement on MCF7 chemoresistance
Effect of WP1066 in MCF7 resistance
To determine potential cytotoxicity of 5μM and 
10μM Jak2/Stat3 inhibitor semiconfluent MCF7Res 
cells were treated for 24 hours with the drug and cell 
viability was assessed by MTT reduction. For measuring 
chemosensisitivity MCF7Res were plated in 96 well-
plates and at the semi-confluence and treated with 5μM 
and 10μM WP1066 for 2 hours or 10μM of doxorubicin, 
for 24 hours. Subsequently, cultures were incubated with 
MTT vital dye and after 3 hours the viable cells were 
measured by solubilizing precipitate formazan from viable 
cells in DMSO, according to routine procedures.
Effect of FDA-approved Tofacitinib in MCF7 
resistance
Before treatment, MCF7 and MCF7-Res cells 
(4x104 cells/cm2) were plated in 96-well plates and 
allowed to recover for 24 hours. Subsequently, at semi-
confluence, cells were treated with Tofacitinib 5μM and 
10μM for 2 hours followed by a Doxorubicin 10μM 
challenge for 24 hours. Cell viability was assessed by 
trypan blue dye exclusion. Apoptosis was analyzed by 
annexin-V-APC binding and 7-AAD (BD Biosciences) 
exclusion in accordance with manufacturer’s instructions. 
Before treatment, MCF7 and MCF7-Res cells (4x104 
cells/cm2) were plated at 96-well plate and allowed to 
recover for 24 hours. At semi-confluence, cells were 
treated with 5μM and 10μM of Tofacitinib for 2 hours; and 
subsequently treated with Doxorubicin 5μM for 24 hours. 
After treatment, cells were harvested (Trypsin-EDTA 0.25 
%) and resuspended at a density of 1x105 cells in 100 μL 
of binding buffer (1X). Annexin-V-APC and 7-AAD were 
added to the cells and the suspension was incubated in 
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the dark for 15 minutes at room temperature. After that, 
200 μL of binding buffer was added to each tube. Cells 
were analyzed by a flow cytometer (FACS Canto II, BD 
Biosciences), 10,000 events. The results were analyzed as 
follows: live cells (double-negative cells), early apoptosis 
(annexin-V positive, 7-AAD negative), late apoptosis 
(double-positive cells), and non-apoptotic cell death 
(annexin-V negative, 7-AAD positive) fractions were 
established.
Statistical analysis
Results are expressed as mean ± standard error of 
the mean (SEM). The statistical analyses were performed 
using analysis of variance (ANOVA) combined with 
appropriate Bonferroni correction. A p value <0.05 was 
considered to be statistically significant. The software 
used was GraphPad Prism 6.
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